Aldesleukin Completed Phase 2 Trials for Renal Cancers / Melanoma (Skin) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00853021Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
NCT00085436DC Vaccine Combined With IL-2 and IFN╬▒-2a in Treating Patients With mRCC
NCT00003091High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma
NCT00031564Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2
NCT00100906Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer
NCT00003568Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00003222Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
NCT00002535Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma
NCT00002669Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00004022Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma
NCT00019383Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma
NCT00019487Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00019721Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00019734Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00019669Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00019994Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00020397Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma
NCT00020358Vaccine Therapy in Treating Patients With Melanoma
NCT00014092Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery
NCT00022438Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment
NCT00054535Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00072085Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma
NCT00079144Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00085423Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00096382Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma